Basilea Pharmaceutica - Zevtera NDA submission pushed to Q323
Basilea has announced that there will be a minor delay in the timing of its new drug application (NDA) for Zevtera (ceftobiprole) to the FDA and it...
258 Views
Basilea Pharmaceutica - Cresemba expansion continues with Japan launch
Basilea has announced that it has received a development-related milestone payment of CHF5m from its Japanese licensing partner, Asahi Kasei...
281 Views
Basilea Pharmaceutica - Profitability sooner than expected
Basilea reported strong FY22 results following the successful execution of its strategic realignment to focus on anti-infectives. The top-line beat...
352 Views
Basilea Pharmaceutica - Strong execution resulting in operating profitability
On the heels of management’s January upward guidance revision, continued strong execution of Basilea’s outlined strategic plan (February 2022) has...
195 Views
Basilea Pharmaceutica - Revenue upside surprise for 2022
Basilea has announced preliminary, unaudited revenue results for FY22, together with an operational update on its commercial and pipeline assets....
329 Views